Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| SRZN | PRESS-RELEASE | mixed | 6/10 | Surrozen closed the second tranche of its March 2025 private placement, raising ~$95.1M in gross proceeds after FDA clea | Oct 20, 2026 |
| TKNO | PRESS-RELEASE | bearish | 5/10 | Alpha Teknova has announced an underwritten public offering of its common stock, with an additional 15% option for under | Oct 20, 2026 |
| TKNO | PRESS-RELEASE | mixed | 6/10 | Alpha Teknova pre-announced preliminary Q3 2026 revenue of $12.5M-$12.7M (up 19-21% YoY) and gross margin expansion of 5 | Oct 20, 2026 |
| AVXL | PRESS-RELEASE | neutral | 3/10 | Anavex provided a corporate update on blarcamesine across three CNS indications. Clinical conduct was completed for DDI | Oct 20, 2026 |
| ONCY | PRESS-RELEASE | neutral | 4/10 | Oncolytics Biotech presented a trial-in-progress abstract at ESMO 2026 for REO 033, a randomized Phase 2 study of pelare | Oct 20, 2026 |
| VVOS | PRESS-RELEASE | mixed | 6/10 | Vivos Therapeutics closed its acquisition of an 11% equity stake in SOD Sciences and a 50% co-ownership interest in SOD' | Oct 19, 2026 |
| JAZZ | PRESS-RELEASE | neutral | 1/10 | Jazz Pharmaceuticals plc announced it will report its Q3 results on November 2, 2026. | Oct 19, 2026 |
| CTY | PRESS-RELEASE | neutral | 5/10 | City Therapeutics closed its upsized IPO of 12,777,777 shares at $18.00 per share, raising approximately $230 million in | Oct 19, 2026 |
| IRON | PRESS-RELEASE | bearish | 7/10 | Disc Medicine announced a $350M underwritten public offering of common stock and pre-funded warrants, with a 30-day unde | Oct 19, 2026 |
| GERN | PRESS-RELEASE | neutral | 2/10 | Geron Corporation granted inducement stock options for 570,000 shares to three new employees at $1.17 per share, a routi | Oct 19, 2026 |
| ABOS | PRESS-RELEASE | neutral | 1/10 | Acumen Pharmaceuticals, Inc. announced it will report its Q3 results on October 26, 2026. | Oct 19, 2026 |
| BCDA | PRESS-RELEASE | bullish | 6/10 | BioCardia announced FDA acceptance of its De Novo pre-submission package for the Helix transendocardial delivery cathete | Oct 19, 2026 |
| PACB | PRESS-RELEASE | neutral | 4/10 | PacBio announced a multi-year strategic collaboration with Verily Health to integrate its HiFi long-read sequencing with | Oct 19, 2026 |
| ONMD | PRESS-RELEASE | neutral | 3/10 | OneMedNet announced its 12th channel partner agreement with a leading global provider of pharmaceutical intelligence and | Oct 19, 2026 |
| INDV | PRESS-RELEASE | neutral | 1/10 | Indivior Inc. announced it will report its Q3 2026 results. | Oct 19, 2026 |
| SUPN | PRESS-RELEASE | neutral | 1/10 | Supernus Pharmaceuticals, Inc. announced it will report its Q3 2026 results on October 29, 2026. | Oct 19, 2026 |
| DWTX | PRESS-RELEASE | mixed | 5/10 | Dogwood Therapeutics announced a $5M private placement from its largest shareholder, CK Life Sciences, at $1.22/share (4 | Oct 19, 2026 |
| ENLV | PRESS-RELEASE | bearish | 6/10 | Enlivex announced a cost reduction plan to wind down non-clinical R&D, cut workforce by ~60%, and reduce management/CEO | Oct 19, 2026 |
| HYPD | PRESS-RELEASE | neutral | 1/10 | Hyperion DeFi, Inc. announced it will host a conference call on November 12 to discuss its Q3 results. | Oct 19, 2026 |
| PHAT | PRESS-RELEASE | neutral | 1/10 | Phathom Pharmaceuticals announced it will report its Q3 2026 results on October 29, 2026. | Oct 19, 2026 |
| URGN | PRESS-RELEASE | bullish | 6/10 | UroGen Pharma announced FDA acceptance of its NDA for UGN-103 (mitomycin) for recurrent low-grade intermediate-risk non- | Oct 19, 2026 |
| BIVI | PRESS-RELEASE | neutral | 5/10 | BioVie presented Phase 2 ADDRESS-LC data for bezisterim in Long COVID at ANA 2026. The trial did not achieve statistical | Oct 19, 2026 |
| CLNN | PRESS-RELEASE | bullish | 8/10 | Clene Inc. announced it has submitted a New Drug Application (NDA) to the FDA seeking accelerated approval of CNM-Au8 fo | Oct 19, 2026 |
| RDHL | PRESS-RELEASE | neutral | 3/10 | RedHill's partner, the University of Oklahoma, received a $2.9 million NCI grant to fund Phase 1b/2 clinical trials of o | Oct 19, 2026 |
| BIIB | PRESS-RELEASE | neutral | 4/10 | Biogen is presenting new 76-week EMPAVELI data at ASN Kidney Week showing sustained proteinuria reduction and continued | Oct 19, 2026 |
| CRMD | PRESS-RELEASE | bullish | 7/10 | CorMedix announced FDA acceptance of its sNDA for REZZAYO (rezafungin) for prophylaxis of invasive fungal disease, with | Oct 19, 2026 |
| TNXP | PRESS-RELEASE | neutral | 3/10 | Tonix Pharmaceuticals announced a poster presentation on TONMYA (cyclobenzaprine HCl sublingual tablets) for fibromyalgi | Oct 19, 2026 |
| IRON | PRESS-RELEASE | bullish | 8/10 | Disc Medicine announced overwhelmingly positive topline results from the APOLLO Phase 3 trial of bitopertin in erythropo | Oct 19, 2026 |
| ATYR | PRESS-RELEASE | neutral | 3/10 | aTyr Pharma announced a research collaboration with Albert Einstein College of Medicine to further develop ATYR2810, its | Oct 19, 2026 |
| MRKR | PRESS-RELEASE | bullish | 5/10 | Marker Therapeutics received a $2.6 million FDA Orphan Products Clinical Trials grant to support a Phase 1 study of its | Oct 19, 2026 |